CTRI/2013/03/003476已完成2 期
A Prospective phase II Open label, monocentric,single arm study to evaluate the safety and efficacy of soybean milk culture Filtrate for anti hair fall and hair regrowth in healthy Indian human volunteers. - NI
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and Female subjects in general good health.
- •Subjects in the age group 20-65 years.
- •Subjects willing to give a written informed consent and agree to come for a regular follow up visit.
- •Subjects willing to abide by and comply with the study protocol.
- •Subjects who have not participated in a similar investigation in the past four weeks.
- •Female Subjects falling under class 2 - class 5 of hair loss severity grade (evaluated as per standard photonumeric 6 point scale)
- •Male subjects falling under type 3 vertex â?? type 5 of hair loss severity grade (evaluated as per Norwood scale)
- •Subjects who agree to have hair wash everyday
- •Subjects who are not on crash dieting
- •Subjects who are willing to refrain from using hair dyes/henna at the time of screening and throughout the study.
- •Subjects willing not to tie hair tightly.
- •Subjects willing to refrain from any type of hair treatment like head massage, oil application (on scalp), perming, etc. during the study duration.
排除标准
- •Subjects who are undergoing hair growth treatment 3 months before screening into the study
- •Subjects who have disorders like eczema, scalp infection, etc at the time of screening.
- •Subjects who have alopecia areata of scalp hair.
- •Subjects who have undergone hair straightening using hot iron or chemicals within 3 months.
- •Subjects who have treatments of actinotherapy or cancer chemotherapy within 6 months before starting study or have a plan to do treatments of them during study terms.
- •Subjects who have history of alcoholism and/ or psychiatric disorder
- •Subjects who use hairpiece during study terms
- •Subjects who have had hair transplant
- •Subjects who take pharmaceutical product which cause hirsutism or sparsed fur (ex. phenytoin)
- •A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
- •Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study.
- •Subjects who are on oral multivitamin tablets containing biotin, zinc, selenium and unwilling to stop the usage 1 month before enrollment into study and through out the study duration.
- •Subjects who are pregnant or become pregnant during study terms, lactating or nursing as established with medical history
- •Chronic illness which may influence the cutaneous state.
- •Subjects participating in other similar cosmetic or therapeutic trial.
- •Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
研究者
相似试验
已完成
2 期
A clinical study to evaluate safety andEffectiveness of the Elure advanced skin whitening products (Advanced whitening lotion andAdvanced whitening night cream) in imparting skin fairness on healthy human volunteers.CTRI/2012/01/002363Syneron P Ltd40
进行中（未招募）
不适用
A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome - MEPOCHUSSChurg-Strauss-SyndromeMedDRA version: 9.1Level: LLTClassification code 10009164Term: Churg Strauss syndromeEUCTR2006-001791-20-DEniversity Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
已完成
3 期
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF rhG-CSF THERAPY FOR MYELOSUPPRESSIVE CHEMOTHERAPY INDUCED NEUTROPENIACTRI/2010/091/000023G C CHEMIE PHARMIE50
已完成
1 期
Phase 1 study to evaluate the pharmacokinetics, safety, tolerability, and taste of tecovirimat pediatric formulationsISRCTN13846827Siga Technologies (United States)12
已完成
2 期
Efficacy and host-pathogen response of heat treatment in patients with Buruli ulcer (BU) using a Phase Change Material (PCM) deviceISRCTN72102977niversity Hospital Heidelberg (Universitätsklinikum Heidelberg) (Germany)100